Glycogen Storage Disease Market Summary

• The Glycogen Storage Disease Market is expected to grow significantly by 2034 in the leading countries (US, UK, EU4, Japan)
• Leading companies in the Glycogen Storage Disease treatment landscape includes, Sanofi, Ultragenyx Pharmaceutical, Amicus Therapeutics, Astellas Pharma, Spark Therapeutics, Maze Therapeutics, Takeda Pharmaceutical, Merck, Novartis, Boehringer Ingelheim, and others.

Key Factors Driving the Glycogen Storage Disease Market:

• Increasing Diagnosis Through Newborn Screening and Genetic Testing

The expansion of newborn screening programs and advancements in genetic testing technologies have significantly improved the early diagnosis of Glycogen Storage Diseases. Improved detection rates allow timely identification of affected individuals, thereby expanding the diagnosed patient population and increasing demand for disease management and therapeutic interventions across the 7MM.

• Advancements in Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy has emerged as a key treatment approach for certain GSD types, particularly Pompe disease (GSD Type II). The clinical success of ERT has validated enzyme-based therapies and encouraged continued investment in next-generation enzyme therapies targeting other GSD subtypes.

• Growing Development of Gene and Molecular Therapies

Rapid progress in gene therapy, mRNA-based therapies, and other advanced biotechnology platforms is creating new opportunities for treating GSDs at the genetic level. Several investigational therapies targeting specific enzyme deficiencies are currently under development, which is expected to significantly expand the treatment landscape in the coming years.

• Strong Orphan Drug Incentives and Regulatory Support

As GSDs are rare inherited metabolic disorders, regulatory agencies in the 7MM provide incentives such as orphan drug designation, market exclusivity, and accelerated approval pathways. These regulatory benefits are encouraging pharmaceutical companies to invest in the development of innovative therapies for GSD.

• Increasing Research and Development Activities

Growing R&D investment by biotechnology and pharmaceutical companies is driving the discovery of novel therapeutic approaches for GSD, including substrate reduction therapies and gene editing technologies. The expanding pipeline of targeted treatments is expected to contribute to future market growth.

• Improved Disease Awareness and Patient Registries

Increasing awareness among healthcare professionals and patients regarding rare metabolic disorders has improved disease recognition and clinical management. The establishment of patient registries and specialized metabolic centers across the 7MM is supporting better disease monitoring and facilitating clinical trial recruitment.

• High Demand for Lifelong Disease Management

Many forms of GSD require long-term management, including pharmacological therapy, strict dietary regimens such as cornstarch therapy, and continuous metabolic monitoring. The chronic nature of the disease creates sustained demand for therapeutic and supportive treatment options.

• Increasing Focus on Rare Disease Research and Funding

Governments, research institutions, and pharmaceutical companies are increasingly investing in rare disease research. Growing funding initiatives and collaborations between academic and industry stakeholders are accelerating the development of innovative therapies for GSD and supporting market growth in the 7MM.

DelveInsight's "Glycogen Storage Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Glycogen Storage Disease, historical and forecasted epidemiology as well as the Glycogen Storage Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glycogen Storage Disease market report provides current treatment practices, emerging drugs, Glycogen Storage Disease market share of the individual therapies, current and forecasted Glycogen Storage Disease market Size from 2021 to 2034 segmented by seven major markets. The Report also covers current Glycogen Storage Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Glycogen Storage Disease market.

Glycogen Storage Disease Understanding

Glycogen Storage Disease Overview

Glycogen Storage Disease (GSD) is a genetic condition in which a lack of certain enzymes makes it difficult for the body to properly store or break down the complex sugar glycogen. GSD affects the liver, muscles, and other body organs. There are numerous varieties of GSD. Glycogen storage diseases are a group of illnesses where the body's stored glycogen cannot be broken down into glucose to produce energy and keep blood sugar levels constant.

Glycogen Storage Disease Diagnosis

Glycogen Storage Disease (GSD) diagnosis involves a combination of clinical evaluation, biochemical testing, and genetic analysis to identify defects in glycogen metabolism. Patients often present with symptoms such as hypoglycemia, hepatomegaly, muscle weakness, or growth delays, which prompt further investigation. Diagnostic assessments typically include blood tests to evaluate glucose, lactate, and lipid levels, along with imaging studies to assess liver or muscle involvement. Enzyme activity assays and molecular genetic testing are commonly used to confirm the specific subtype of GSD. Early and accurate diagnosis is essential for guiding appropriate disease management and preventing long-term complications.

Glycogen Storage Disease Treatment

Glycogen Storage Disease (GSD) treatment focuses on managing metabolic imbalances and preventing complications associated with impaired glycogen metabolism. Therapeutic strategies primarily involve dietary management, including frequent meals, complex carbohydrate intake, and uncooked cornstarch supplementation to maintain stable blood glucose levels. In certain subtypes, additional interventions such as lipid-lowering agents, vitamin supplementation, or medications to manage metabolic complications may be required. For severe cases involving liver dysfunction, liver transplantation may be considered. Advances in research, including enzyme replacement therapy and gene therapy approaches, are also being explored to improve long-term outcomes for patients with GSD.

Glycogen Storage Disease Epidemiology 

The Glycogen Storage Disease epidemiology section provides insights about the historical and current Glycogen Storage Disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Glycogen Storage Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from the Glycogen Storage Disease Patient Pool Analysis

The disease epidemiology covered in the report provides historical as well as forecasted Glycogen Storage Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Glycogen Storage Disease Epidemiology

The epidemiology segment also provides the Glycogen Storage Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Glycogen Storage Disease Recent Developments

• In August 2025, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) began a rolling Biologics License Application (BLA) submission to the FDA for DTX401, its AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa). The non-clinical and clinical modules have been submitted, with completion of the full BLA, including the CMC module, planned for Q4 2025.
• In July 2025, Ultragenyx Pharmaceutical Inc., a leader in rare and ultra-rare genetic disease therapies, continues to stand out as a top growth stock. Its portfolio features commercial products and a robust late-stage pipeline targeting conditions like Sanfilippo syndrome type A, osteogenesis imperfecta, Angelman syndrome, and glycogen storage diseases.

Glycogen Storage Disease Drug Analysis

The drug chapter segment of the Glycogen Storage Disease report encloses the detailed analysis of Glycogen Storage Disease marketed drugs and late-stage (Phase-III and Phase-II) Glycogen Storage Disease pipeline drugs. It also helps to understand the Glycogen Storage Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Glycogen Storage Disease Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Glycogen Storage Disease treatment.

Glycogen Storage Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Glycogen Storage Disease treatment.

Glycogen Storage Disease Market Outlook

The Glycogen Storage Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Glycogen Storage Disease market trends by analyzing the impact of current Glycogen Storage Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Glycogen Storage Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Glycogen Storage Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Glycogen Storage Disease market in 7MM is expected to witness a major change in the study period 2021-2034.

The United States Market Outlook

This section provides the total Glycogen Storage Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Glycogen Storage Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Glycogen Storage Disease market size and market size by therapies in Japan is also mentioned.

Glycogen Storage Disease Drugs Uptake

This section focuses on the rate of uptake of the potential Glycogen Storage Disease drugs recently launched in the Glycogen Storage Disease market or expected to get launched in the market during the study period 2021-2034. The analysis covers Glycogen Storage Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.  

Glycogen Storage Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Glycogen Storage Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Glycogen Storage Disease Clinical Trials Analysis

The Glycogen Storage Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Glycogen Storage Disease key players involved in developing targeted therapeutics.

Glycogen Storage Disease Pipeline Development Activities

The Glycogen Storage Disease report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Glycogen Storage Disease emerging therapies.

Reimbursement Scenario in Glycogen Storage Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL Views on Glycogen Storage Disease

To keep up with current Glycogen Storage Disease market trends, we take KOLs and SMEs ' opinion working in the Glycogen Storage Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Glycogen Storage Disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Glycogen Storage Disease Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Glycogen Storage Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Glycogen Storage Disease Market Companies

Some of the key players of the Glycogen Storage Disease market include Sanofi, Ultragenyx Pharmaceutical, Amicus Therapeutics, Astellas Pharma, Spark Therapeutics, Maze Therapeutics, Takeda Pharmaceutical, Merck, Novartis, Boehringer Ingelheim, and others.

Scope of the Glycogen Storage Disease Market Report

• The report covers the descriptive overview of Glycogen Storage Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Glycogen Storage Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Glycogen Storage Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Glycogen Storage Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Glycogen Storage Disease market

Glycogen Storage Disease Market Report Highlights

• In the coming years, the Glycogen Storage Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Glycogen Storage Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Glycogen Storage Disease. The launch of emerging therapies will significantly impact the Glycogen Storage Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Glycogen Storage Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Glycogen Storage Disease Report Insights

• Glycogen Storage Disease Patient Population
• Therapeutic Approaches
• Glycogen Storage Disease Pipeline Analysis
• Glycogen Storage Disease Market Size and Trends
• Glycogen Storage Disease Market Opportunities
• Impact of upcoming Glycogen Storage Disease Therapies

Glycogen Storage Disease Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Glycogen Storage Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Glycogen Storage Disease Report Assessment

• Current Treatment Practices
• Unmet Needs
• Glycogen Storage Disease Pipeline Product Profiles
• Glycogen Storage Disease Market Attractiveness
• Market Drivers and Barriers

Key Questions Answered in the Glycogen Storage Disease Market Report

Market Insights:

• What was the Glycogen Storage Disease drug class share (%) distribution in 2021 and how it would look like in 2034?
• What would be the Glycogen Storage Disease total market size as well as market size by therapies across the 7MM during the forecast period (2022-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Glycogen Storage Disease market size during the forecast period (2022-2034)?
• At what CAGR, the Glycogen Storage Disease market is expected to grow by 7MM during the forecast period (2022-2034)?
• What would be the Glycogen Storage Disease market outlook across the 7MM during the forecast period (2022-2034)?
• What would be the Glycogen Storage Disease market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Glycogen Storage Disease?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Glycogen Storage Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Glycogen Storage Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Glycogen Storage Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of Glycogen Storage Disease during the forecast period (2022-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2022-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Glycogen Storage Disease treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Glycogen Storage Disease in the USA, Europe, and Japan?
• What are the Glycogen Storage Disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Glycogen Storage Disease?
• How many therapies are in-development by each company for Glycogen Storage Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Glycogen Storage Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Glycogen Storage Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glycogen Storage Disease and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Glycogen Storage Disease?
• What are the global historical and forecasted market of Glycogen Storage Disease?

Reasons to buy the Glycogen Storage Disease Market Report

• The report will help in developing business strategies by understanding trends shaping and driving the Glycogen Storage Disease market
• To understand the future market competition in the Glycogen Storage Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Glycogen Storage Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Glycogen Storage Disease market
• To understand the future market competition in the Glycogen Storage Disease market